InterMune's Roch Deal Sends Peer Group Up Monday

InterMune Inc.'s ITMN agreement to be acquired by Roche RHHBY for $74 a share sent similar drug development companies up in early trading Monday. InterMune gained 35 percent to $73.08 a share. Infinity Pharmaceuticals Inc. INFI rose more than 4 percent to $11.42 a share; Gilead Sciences, Inc. GILD picked up 3 percent to $107.1 a share; Synta Pharmaceuticals Corp. SNTA gained nearly 3 percent to $4.11 a share and Rigel Pharmaceuticals Inc. RIGL gained 2 percent to $2.64. InterMune, which makes a single product for treatment of pulmonary fibrosis approved only in Europe and Canada, had been rumored for sale as early as March. Talk surfaced again earlier this month, with the mention of potential acquirers including Sanofi SNY, GlaxoSmithKline GSK and Actelion ALIOF. Roche finally inked an $8.3 billion deal Sunday.